Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung carcinoma (NSCLC) presents a significant global health challenge due to its poor prognosis and high mortality rates.
• Platinum-based chemotherapy remains a primary treatment, but advancements in molecular targeted therapy are revolutionizing patient care.
• Epidermal growth factor receptor (EGFR) mutations are a key focus in developing novel therapeutic strategies for NSCLC.

Purpose of the Study:

• To review the latest research on epidermal growth factor receptor (EGFR) pathogenic mutations in NSCLC.
• To provide an overview of established EGFR-tyrosine kinase inhibitors (TKIs) across four generations.
• To discuss the mechanisms of action, acquired resistance, clinical applications, and future perspectives of EGFR-targeted therapies.

Main Methods:

• Literature review of recent studies on EGFR mutations and targeted therapies in NSCLC.
• Analysis of data on first- to fourth-generation EGFR-TKIs, including their efficacy and resistance patterns.
• Synthesis of information on clinical applications and future research challenges.

Main Results:

• Detailed characterization of various EGFR pathogenic mutations driving NSCLC.
• Comprehensive summary of EGFR-TKIs, detailing their evolution, mechanisms, and clinical utility.
• Identification of common resistance mechanisms and strategies to overcome them.

Conclusions:

• EGFR-targeted therapy has transformed NSCLC treatment, offering personalized therapeutic options.
• Understanding EGFR mutation types and TKI resistance is crucial for optimizing treatment outcomes.
• Continued research into novel inhibitors and combination strategies is essential for addressing challenges in NSCLC management.